Nanopath

Cambridge, United States Founded: 2019 • Age: 7 yrs
Point-of-care molecular diagnostics for womens health are provided by Nanopath.
Request Access

About Nanopath

Nanopath is a company based in Cambridge (United States) founded in 2019 by Alison Burklund and Amogha Tadimety.. Nanopath has raised $10 million across 5 funding rounds from investors including NIH, Norwest Venture Partners and National Science Foundation. Nanopath offers products and services including Molecular Diagnostic Platform. Nanopath operates in a competitive market with competitors including N-of-One, OrigiMed, Range Bio, Coral Genomics and VSense, among others.

  • Headquarter Cambridge, United States
  • Founders Alison Burklund, Amogha Tadimety
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Nanopath Inc.
Operational Areas
Healthcare → Health Technology & Digital Health
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $10 M (USD)

    in 5 rounds

  • Latest Funding Round
    $5.34 M (USD), Debt – Conventional

    Jan 24, 2025

  • Investors
    NIH

    & 7 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Nanopath

Nanopath offers a comprehensive portfolio of products and services, including Molecular Diagnostic Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Enables scalable point-of-care testing for disease diagnosis.

Funding Insights of Nanopath

Nanopath has successfully raised a total of $10M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $5.34 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Debt – Conventional — $5.3M
  • First Round

    (01 Jan 2022)

  • Investors Count 8
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2025 Amount Debt – Conventional - Nanopath Valuation

investors

May, 2024 Amount Grant - Nanopath Valuation

investors

Mar, 2024 Amount Grant - Nanopath Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Nanopath

Nanopath has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Norwest Venture Partners and National Science Foundation. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors.
Founded Year Domain Location
Venture capital fund focused on early-stage healthcare startups
Founded Year Domain Location
Capital is provided to women-led ventures in early stages.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Nanopath

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Nanopath

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Nanopath Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Nanopath

Nanopath operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as N-of-One, OrigiMed, Range Bio, Coral Genomics and VSense, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Molecular profiles are analyzed for clinical decision support in oncology.
domain founded_year HQ Location
Genetic sequencing is utilized for personalized cancer diagnostics and counseling.
domain founded_year HQ Location
Provider of solutions for health monitoring based on translational proteomics
domain founded_year HQ Location
Genomic data is analyzed for personalized drug development optimization.
domain founded_year HQ Location
Developer of semiconductor biosensor technology
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Nanopath

Frequently Asked Questions about Nanopath

When was Nanopath founded?

Nanopath was founded in 2019 and raised its 1st funding round 3 years after it was founded.

Where is Nanopath located?

Nanopath is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Who is the current CEO of Nanopath?

Alison Burklund is the current CEO of Nanopath. They have also founded this company.

Is Nanopath a funded company?

Nanopath is a funded company, having raised a total of $10M across 5 funding rounds to date. The company's 1st funding round was a Grant of $996.73K, raised on Jan 01, 2022.

What does Nanopath do?

Nanopath was founded in 2019 and is based in Cambridge, United States. A nanotechnology-based platform for point-of-care molecular diagnostics in womens health is developed and offered. Assay development is focused on pelvic and gynecologic infections to enhance patient outcomes through improved diagnostic processes. Operations center on advancing the sectors diagnostic capabilities in a clinical setting.

Who are the top competitors of Nanopath?

Nanopath's top competitors include Range Bio, OrigiMed and N-of-One.

What products or services does Nanopath offer?

Nanopath offers Molecular Diagnostic Platform.

Who are Nanopath's investors?

Nanopath has 8 investors. Key investors include NIH, Norwest Venture Partners, National Science Foundation, SV Health Investors, and GingerBread Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available